<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812940</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln 1717</org_study_id>
    <nct_id>NCT02812940</nct_id>
  </id_info>
  <brief_title>Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT</brief_title>
  <acronym>OCTET-Ever</acronym>
  <official_title>A Single-centre Study of Certican (Everolimus) as Prophylaxis for Graft-versus-Host Disease Following Post-Transplantation Cyclophosphamide After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for&#xD;
      Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after&#xD;
      allogeneic hematopoietic stem cell transplantation in patients with haematological&#xD;
      malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title of the clinical study: A single-centre study of Certican (everolimus) as Prophylaxis&#xD;
      for Graft-versus-Host Disease following Post-Transplantation Cyclophosphamide after&#xD;
      Allogeneic Stem Cell Transplantation (OCTET-EVER)&#xD;
&#xD;
      Indication: Patients with haematological malignancies after allogeneic haematopoietic stem&#xD;
      cell transplantation with a matched related or unrelated donor following reduced intensity&#xD;
      conditioning and post-transplantation cyclophosphamide&#xD;
&#xD;
      Phase: Phase II clinical study&#xD;
&#xD;
      Type of study, study design, methodology: Single centre single arm clinical trial, A'Hern's&#xD;
      single stage phase II procedure&#xD;
&#xD;
      Number of subjects: 20 (17 total evaluable)&#xD;
&#xD;
      Primary study objective To assess the efficacy of short-term everolimus as GvHD prophylaxis&#xD;
      in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell&#xD;
      transplantation in patients with haematological malignancies and to describe the influence of&#xD;
      the modified immunosuppression concept on the incidence and severity of acute GvHD, relapse&#xD;
      rates, minimal residual disease, immune reconstitution and chimerism.&#xD;
&#xD;
      Medical condition or disease to be investigated:&#xD;
&#xD;
      • Patients with haematological malignancies after allogeneic haematopoietic stem cell&#xD;
      transplantation with a matched related or unrelated donor following reduced intensity&#xD;
      conditioning and post-transplantation cyclophosphamide&#xD;
&#xD;
      Name of investigational medicinal product (IMP): Everolimus (Certican®) Investigational&#xD;
      medicinal product - dosage and method of administration: 1,5mg per os twice a day (target&#xD;
      blood level 5 to 10ng/ml) from day +5 to day +100 after allogeneic stem cell transplantation&#xD;
&#xD;
      Duration of treatment: The treatment will be given from day +5 to day +100 after allogeneic&#xD;
      stem cell transplantation. The observation time will last from day +5 to day +130. Incidence&#xD;
      of chronic GvHD, overall survival and relapse incidence will be recorded on d+365 and d+720&#xD;
      after transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GvHD III-IV° until day +100 after allogenic stem cell transplantation</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>GvHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GvHD II-IV° until day +100 after allogenic stem cell transplantation</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe chronic GvHD</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>cGvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of overall chronic GvHD</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>cGvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>Relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>720 days after transplantation</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>Number of CD3, CD4, CD8, CD20 and CD56 positive cells in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>absolute neutrophil count &gt; 500/ul and platelet count &gt; 50.000/ul</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>day 100 after transplantation</time_frame>
    <description>% donor cells in peripheral blood or bone marrow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Graft-versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Everolimus as part of GvHD prophylaxis after allogeneic SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus from day +5 to day +100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>GvHD prophylaxis</description>
    <arm_group_label>Everolimus as part of GvHD prophylaxis after allogeneic SCT</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with haematological malignancies after allogeneic haematopoietic stem cell&#xD;
             transplantation with a matched related or unrelated donor following reduced intensity&#xD;
             conditioning and post-transplantation cyclophosphamide&#xD;
&#xD;
        Principal inclusion criteria:&#xD;
&#xD;
        • Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to everolimus&#xD;
&#xD;
          -  Presence or history of Microangiopathy&#xD;
&#xD;
          -  Presence of uncontrolled infections&#xD;
&#xD;
          -  Severe organ dysfunction defined as:&#xD;
&#xD;
          -  Cardiac left ventricular ejection fraction (LVEF) of less than 35%&#xD;
&#xD;
          -  Diffusing lung capacity (DLCO) of less than 40%&#xD;
&#xD;
          -  Total lung capacity (TLC) of less than 40%&#xD;
&#xD;
          -  Forced expiratory volume (FEV1) of less than 40%&#xD;
&#xD;
          -  Total bilirubin &gt;3mg/dl&#xD;
&#xD;
          -  Creatinine-clearance of less than 40 ml/min&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Participation in other experimental drug trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Scheid, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Christoph Scheid</investigator_full_name>
    <investigator_title>Prof. Dr. Christoph Scheid</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

